Andrew Baum
Stock Analyst at Citigroup
(3.86)
# 779
Out of 4,479 analysts
28
Total ratings
84.38%
Success rate
19.09%
Average return
Main Sectors:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly | Maintains: Buy | $675 → $895 | $906.71 | -1.29% | 5 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $12.24 | -18.30% | 3 | Oct 20, 2023 | |
| PFE Pfizer | Maintains: Neutral | $42 → $35 | $27.83 | +25.76% | 4 | Oct 16, 2023 | |
| MRK Merck & Co. | Upgrades: Buy | $105 → $130 | $127.72 | +1.79% | 6 | Apr 13, 2023 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $75 → $90 | $40.45 | +122.50% | 4 | May 26, 2022 | |
| ABBV AbbVie | Reiterates: Buy | $155 → $170 | $165.96 | +2.43% | 4 | Mar 1, 2022 | |
| RPRX Royalty Pharma | Upgrades: Buy | n/a | $25.88 | - | 1 | Oct 29, 2021 | |
| GSK GSK | Downgrades: Neutral | n/a | $38.21 | - | 1 | Jul 5, 2017 |
Eli Lilly
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $906.71
Upside: -1.29%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $12.24
Upside: -18.30%
Pfizer
Oct 16, 2023
Maintains: Neutral
Price Target: $42 → $35
Current: $27.83
Upside: +25.76%
Merck & Co.
Apr 13, 2023
Upgrades: Buy
Price Target: $105 → $130
Current: $127.72
Upside: +1.79%
Bristol-Myers Squibb Company
May 26, 2022
Maintains: Buy
Price Target: $75 → $90
Current: $40.45
Upside: +122.50%
AbbVie
Mar 1, 2022
Reiterates: Buy
Price Target: $155 → $170
Current: $165.96
Upside: +2.43%
Royalty Pharma
Oct 29, 2021
Upgrades: Buy
Price Target: n/a
Current: $25.88
Upside: -
GSK
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $38.21
Upside: -